T
RVNC

TCWP’s Revance Therapeutics, Inc. RVNC Stock Holding History

TCWP’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-39
Closed – – 1844
2022
Q1 		$0 Buy
+39
New +$591 ﹤0.01% 1938

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

TCWP's RVNC Position: Q2 2022 in Review

TCWP sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2022, closing a stake of 39 shares.

TCWP first reported a position in RVNC in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 161 funds tracked by Wall St. Rank hold RVNC as of Q2 2022.

  • TCWP reported no remaining Revance Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
  • TCWP sold 39 Revance Therapeutics, Inc. shares in Q2 2022.
  • TCWP first reported a position in Revance Therapeutics, Inc. in Q1 2022 and held it in 1 quarter.
  • TCWP's Revance Therapeutics, Inc. position peaked at $0 in Q1 2022.
  • 161 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.